Online inquiry

IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14219MR)

This product GTTS-WQ14219MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14219MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11130MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ12962MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ14403MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ5092MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ3806MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ4992MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ5980MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ9684MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW